Ask AI
ProCE Banner Activity

Our Experiences and Considerations With Current and Emerging BTK Inhibitors for R/R CLL/SLL

Clinical Thought

Expert faculty address audience questions from a live event and discuss their experience and considerations with current and emerging BTK inhibitors in R/R CLL/SLL. 

Released: December 26, 2023

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Lilly and Merck Sharp & Dohme, LLC.

Lilly

Merck Sharp & Dohme, LLC

Faculty Disclosure

Primary Author

Jennifer R. Brown, MD, PhD

Director, CLL Center, and Institute Physician
Dana-Farber Cancer Institute
Worthington and Margaret Collette Professor of Medicine in the field of Hematologic Oncology
Harvard Medical School
Boston, Massachusetts

Jennifer R. Brown, MD, PhD: consultant/advisor/speaker: AbbVie, Acerta/AstraZeneca, Alloplex, Beigene, Biotherapeutics, Genentech/Roche, Grifols Worldwide Operations, IOnctura, Kite, Loxo/Lilly, Merck, Numab Therapeutics, Pfizer, Pharmacyclics; researcher: BeiGene, Gilead, IOnctura, Loxo/Lilly, MEI Pharma, SecuraBio, TG Therapeutics.

Florence Cymbalista, MD, PhD

Professor of Hematology
Sorbonne Paris Nord University
Bobigny, France

Florence Cymbalista, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, Beigene, Janssen, Lilly.